AURA

Rating neutralAI MemoPost-earnings T+3

Aura Biosciences

As of 2026-08-08/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Expanded authorized-share capacity • 2026-08-05

Base target: $8 / p=50% prob

Biggest risk

No confirmed August earnings print or new clinical readout was identified, so the scheduled follow-up does not currently improve forward visibility. Milestone slippage, unfavorable data, regulatory setbacks, and future dilution remain material risks; the approved share authorization increases the financing overhang [#8-K-2026-08-05].

Invalidation

Break below $5 or thesis failure.

What would change my mind?

Bel-sar could deliver multiple 2026 development updates, complete CoMpass enrollment, and preserve a path to potentially transformative 2H 2027 topline data. The May update also indicated financing support and expected runway into 2H 2028 [#SEC-8K-2026-05-11].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-08-08

Base target

p=50%

Bull target

$13

p=20%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Earnings follow-up lacks a verified company print
Phase 3 CoMpass topline data
Bel-sar could deliver multiple 2026 development updates, complete CoMpass enrollment, and preserve a path to potentially transformative 2H 2027 topline data.

BearKey bullets

2026 NMIBC, choroidal-metastases, and ocular-surface data remain unverified, leaving weak near-term visibility.
A 10% owner reported an open-market sale of approximately 6.9 million shares at $5.64 on May 7, 2026; this is a sentiment risk but not evidence of operating performance [#SEC-FORM4-2026-05-11].
Clinical and regulatory outcomes are binary and may not support registration or commercialization.

WatchKey bullets

Expanded authorized-share capacity

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $8 (p=50%)

Target spread vs base: +67% / -40%

Scenario probabilities

Bull Target: $13 (p=20%)Base Target: $8 (p=50%)Bear Target: $5 (p=30%)

Commentary

The scheduled post-earnings trigger appears unconfirmed: checked company materials show the August 5 filing was a stockholder vote rather than an earnings release, and the IR quarterly-results page still lists Q1 2026 as the latest 2026 result. The August 7 anchor price was $7.99, but no reliable earnings-linked price reaction or analyst revision signal was found. Sentiment therefore remains cautious and monitoring-oriented, with low coverage and limited fresh forward evidence.

As of 2026-08-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Earnings follow-up lacks a verified company print
Phase 3 CoMpass topline data

Scenarios

Bull Target (Scenario probability)

$13 / p=20% prob

Base Target (Scenario probability)

$8 / p=50% prob

Bear Target (Scenario probability)

$5 / p=30% prob

Analysis 2026-08-08 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.10

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-05
Expanded authorized-share capacity
Stockholders approved increasing authorized common shares from 150 million to 500 million. This improves financing flexibility but also creates a potential dilution overhang for a clinical-stage company [#8-K-2026-08-05].
Prob 95.00% • Move -5.00% • Priced-in 80.00%
EVENT2026-11-06
2026 bel-sar clinical data windows
Management's latest confirmed update kept early data from the choroidal-metastases program, ocular-surface proof-of-concept data, and initial NMIBC three-month data on the 2026 calendar. Exact timing and results remain unverified, so this is a monitoring catalyst rather than a high-conviction trade setup [#SEC-8K-2026-05-11].
Prob 55.00% • Move 20.00% • Priced-in 30.00%
EVENT2026-11-06
CoMpass enrollment-completion status update
Aura previously targeted completion of Phase 3 CoMpass enrollment by mid-2026. A confirmed completion update would reduce execution uncertainty, while slippage would likely pressure sentiment; no current confirmation was found in the checked sources [#SEC-8K-2026-05-11].
Prob 60.00% • Move 12.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

Earnings follow-up lacks a verified company print
2026-08-08
The scheduled August 6 T3 follow-up could not be reconciled to a confirmed Q2 2026 earnings release. The official IR quarterly-results page still lists Q1 2026 as the latest 2026 result; no verified revenue/EPS surprise, guidance revision, analyst revision, or earnings-linked market reaction is available. The latest confirmed operating update cited CoMpass progress, 2026 clinical milestones, and runway into 2H 2028 [#SEC-8K-2026-05-11] [#PR-EARNINGS-2026-05-12].
Prob 90% • Move -3% • Priced-in 70%

Long-term Catalysts

Months to a year

Phase 3 CoMpass topline data
2027-08-08
The pivotal 15-month primary-endpoint topline readout remains targeted for the second half of 2027. It is the main potential rerating event, but its distance and clinical binary risk keep AURA in monitoring mode [#SEC-8K-2026-05-11].
Prob 55% • Move 70% • Priced-in 25%

Risks

2026 NMIBC, choroidal-metastases, and ocular-surface data remain unverified, leaving weak near-term visibility.
A 10% owner reported an open-market sale of approximately 6.9 million shares at $5.64 on May 7, 2026; this is a sentiment risk but not evidence of operating performance [#SEC-FORM4-2026-05-11].
Clinical and regulatory outcomes are binary and may not support registration or commercialization.
CoMpass enrollment completion and the 2H 2027 topline timeline may slip.
No verified Q2 earnings surprise, guidance change, analyst revision, or post-print market-reaction attribution is available.
The authorized-share increase from 150 million to 500 million creates potential future dilution [#8-K-2026-08-05].

Peers

Symbol	Summary
XFOR	Small-cap clinical biotech where valuation depends heavily on milestone timing, readout credibility, and financing durability; useful as an event-risk comparator despite different disease focus.
RLMD	Event-driven clinical biotech with sharp sensitivity to trial updates and capital runway; limited operating overlap makes it a sentiment comparator rather than a valuation peer.
PALI	Looser micro-cap biotech comparator that helps frame downside from weak clinical signals or funding pressure, not indication-specific benchmarking.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-08

Loading AI feed…

Symbol

Summary

XFOR

Small-cap clinical biotech where valuation depends heavily on milestone timing, readout credibility, and financing durability; useful as an event-risk comparator despite different disease focus.

RLMD

Event-driven clinical biotech with sharp sensitivity to trial updates and capital runway; limited operating overlap makes it a sentiment comparator rather than a valuation peer.

PALI

Looser micro-cap biotech comparator that helps frame downside from weak clinical signals or funding pressure, not indication-specific benchmarking.